LeadDiscovery™
Kinase and GPCR solutions
tailored to address your target
Exelgen has invested significant R&D effort to establish a rich seam of early-stage, novel chemistry assets containing chemotypes with confirmed activity towards both kinase and GPCR disease targets. Offering you a route straight to lead optimisation for these targets, compounds can be accessed under two business models.
GPCR LeadDiscovery™ and Kinase LeadDiscovery™ Screening Collections
- Ideas and designs derived from experienced medicinal chemists using our state-of-the-art proprietary software and tools
- Compound collections ready-prepared for you to screen against your proprietary targets under a low-risk business model
- Exclusive partnership options to develop the targeted libraries into lead series and optimised leads utilising Exelgen's accelerated discovery chemistry processes
|
Early-stage in-licensing
Additionally, our LeadDiscovery™ programmes have identified novel, early stage compounds with proven activity and associated indications and patent position.
For further information about GPCR and Kinase LeadDiscovery and licensing opportunities, please view the pdfs or contact
.
|
